Shanghai United Imaging Healthcare Co., Ltd.

Money comes mainly from one-time sales of imaging and radiotherapy equipment, most of it sold through independent distributors rather than directly to customers, with a smaller recurring stream from maintenance contracts purchased once the initial warranty period ends, and a minor software component. It has generated positive net income in each of the last several years CompanyGraph has on record.

Growth appears to come from two reinforcing sources: extending regulatory approval into more country markets one clearance at a time, and expanding the installed base of equipment already placed with customers, which supports a growing maintenance and service business built on its overseas service and parts network. This is CompanyGraph's reading of how the pieces the company discloses fit together, not a trend measured directly from financial results.

It depends on imported components it identifies by name, including X-ray tube assemblies, superconducting wires and scintillation crystals, which it describes as materials now subject to tariff exposure. It also depends on a network of independent distributors to reach much of its customer base, and it names business-cooperation risk within that distribution model as one of its own flagged risks.

Its systems are used by medical institutions, research institutes and universities, along with pharmaceutical companies for some of its life-science instruments. Revenue is spread across a broad customer base rather than concentrated in a small number of accounts.

Hundreds of other companies CompanyGraph tracks run the same kind of approval-gated production system, so this economic shape by itself is common rather than rare, and the company states that its own position instead rests on breadth across its product portfolio, integrated clinical solutions, and control of core technology and key components through a self-operated research, production and service chain. It reports leading domestic market share across most of its product lines, but whether that breadth is something rivals cannot replicate is not something CompanyGraph can verify from what is on file.

The industry classification frames this company as one whose scale is capped by how fast its products can clear formal approval gates, rather than by unlimited demand. Consistent with that, the company's own account names regulatory approval and product-registration cycles, at home and abroad, as what it sees as limiting its growth, and it further states that tighter Chinese registration or production and operating oversight could constrain both new product launches and existing product output and sales.

The company's own risk disclosures put technology risk first: the leakage of core technical know-how or infringement of its key technologies is the risk category it names before any other. Immediately after that, it names operational risk tied to its reliance on independent distributors for the majority of its sales, along with still-developing overseas sales channels, integration with local distributors abroad, and exposure to currency movements and customer receivables.

It operates under separate national regulatory approval systems at once, including registration with China's National Medical Products Administration, review or clearance from the U.S. Food and Drug Administration, and CE certification in the European Union, and it states that these overseas approval barriers and registration cycles are lengthy. It also names direct exposure to the trade relationship between China and the United States, since some exports face additional tariffs entering the American market while some imported components face additional Chinese tariffs, and it settles part of its business in US dollars and euros, which it hedges against currency movement.